Development and validation of a novel integrated clinical-genomic risk group classification for localized prostate cancer

Daniel E. Spratt, Jingbin Zhang, Maria Santiago-Jiḿenez, Robert T. Dess, John W. Davis, Robert B. Den, Adam P. Dicker, Christopher J. Kane, Alan Pollack, Radka Stoyanova, Firas Abdollah, Ashley E. Ross, Adam Cole, Edward Uchio, Josh M. Randall, Hao Nguyen, Shuang G. Zhao, Rohit Mehra, Andrew G. Glass, Lucia L.C. LamJijumon Chelliserry, Marguerite Du Plessis, Voleak Choeurng, Maria Aranes, Tyler Kolisnik, Jennifer Margrave, Jason Alter, Jennifer Jordan, Christine Buerki, Kasra Yousefi, Zaid Haddad, Elai Davicioni, Edouard J. Trabulsi, Stacy Loeb, Ashutosh Tewari, Peter R. Carroll, Sheila Weinmann, Edward M. Schaeffer, Eric A. Klein, R. Jeffrey Karnes, Felix Y. Feng, Paul L. Nguyen

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

Purpose It is clinically challenging to integrate genomic-classifier results that report a numeric risk of recurrence into treatment recommendations for localized prostate cancer, which are founded in the framework of risk groups. We aimed to develop a novel clinical-genomic risk grouping system that can readily be incorporated into treatment guidelines for localized prostate cancer. Materials and Methods Two multicenter cohorts (n = 991) were used for training and validation of the clinical-genomic risk groups, and two additional cohorts (n = 5,937) were used for reclassification analyses. Competing risks analysis was used to estimate the risk of distant metastasis. Time-dependent c-indices were constructed to compare clinicopathologic risk models with the clinical-genomic risk groups. Results With a median follow-up of 8 years for patients in the training cohort, 10-year distant metastasis rates for National Comprehensive Cancer Network (NCCN) low, favorable-intermediate, unfavorableintermediate, and high-risk were 7.3%, 9.2%, 38.0%, and 39.5%, respectively. In contrast, the threetier clinical-genomic risk groups had 10-year distant metastasis rates of 3.5%, 29.4%, and 54.6%, for low-, intermediate-, and high-risk, respectively, which were consistent in the validation cohort (0%, 25.9%, and 55.2%, respectively). C-indices for the clinical-genomic risk grouping system (0.84; 95% CI, 0.61 to 0.93) were improved over NCCN (0.73; 95% CI, 0.60 to 0.86) and Cancer of the Prostate Risk Assessment (0.74; 95%CI, 0.65 to 0.84), and 30%of patients using NCCN low/intermediate/high would be reclassified by the new three-tier system and 67% of patients would be reclassified from NCCN six-tier (very-low- to very-high-risk) by the new six-tier system. Conclusion A commercially available genomic classifier in combination with standard clinicopathologic variables can generate a simple-to-use clinical-genomic risk grouping that more accurately identifies patients at low, intermediate, and high risk formetastasis and can be easily incorporated into current guidelines to better risk-stratify patients.

Original languageEnglish (US)
Pages (from-to)581-590
Number of pages10
JournalJournal of Clinical Oncology
Volume36
Issue number6
DOIs
StatePublished - Feb 20 2018

Fingerprint

Prostatic Neoplasms
Neoplasm Metastasis
Neoplasms
Guidelines

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Spratt, D. E., Zhang, J., Santiago-Jiḿenez, M., Dess, R. T., Davis, J. W., Den, R. B., ... Nguyen, P. L. (2018). Development and validation of a novel integrated clinical-genomic risk group classification for localized prostate cancer. Journal of Clinical Oncology, 36(6), 581-590. https://doi.org/10.1200/JCO.2017.74.2940

Development and validation of a novel integrated clinical-genomic risk group classification for localized prostate cancer. / Spratt, Daniel E.; Zhang, Jingbin; Santiago-Jiḿenez, Maria; Dess, Robert T.; Davis, John W.; Den, Robert B.; Dicker, Adam P.; Kane, Christopher J.; Pollack, Alan; Stoyanova, Radka; Abdollah, Firas; Ross, Ashley E.; Cole, Adam; Uchio, Edward; Randall, Josh M.; Nguyen, Hao; Zhao, Shuang G.; Mehra, Rohit; Glass, Andrew G.; Lam, Lucia L.C.; Chelliserry, Jijumon; Du Plessis, Marguerite; Choeurng, Voleak; Aranes, Maria; Kolisnik, Tyler; Margrave, Jennifer; Alter, Jason; Jordan, Jennifer; Buerki, Christine; Yousefi, Kasra; Haddad, Zaid; Davicioni, Elai; Trabulsi, Edouard J.; Loeb, Stacy; Tewari, Ashutosh; Carroll, Peter R.; Weinmann, Sheila; Schaeffer, Edward M.; Klein, Eric A.; Karnes, R. Jeffrey; Feng, Felix Y.; Nguyen, Paul L.

In: Journal of Clinical Oncology, Vol. 36, No. 6, 20.02.2018, p. 581-590.

Research output: Contribution to journalArticle

Spratt, DE, Zhang, J, Santiago-Jiḿenez, M, Dess, RT, Davis, JW, Den, RB, Dicker, AP, Kane, CJ, Pollack, A, Stoyanova, R, Abdollah, F, Ross, AE, Cole, A, Uchio, E, Randall, JM, Nguyen, H, Zhao, SG, Mehra, R, Glass, AG, Lam, LLC, Chelliserry, J, Du Plessis, M, Choeurng, V, Aranes, M, Kolisnik, T, Margrave, J, Alter, J, Jordan, J, Buerki, C, Yousefi, K, Haddad, Z, Davicioni, E, Trabulsi, EJ, Loeb, S, Tewari, A, Carroll, PR, Weinmann, S, Schaeffer, EM, Klein, EA, Karnes, RJ, Feng, FY & Nguyen, PL 2018, 'Development and validation of a novel integrated clinical-genomic risk group classification for localized prostate cancer', Journal of Clinical Oncology, vol. 36, no. 6, pp. 581-590. https://doi.org/10.1200/JCO.2017.74.2940
Spratt, Daniel E. ; Zhang, Jingbin ; Santiago-Jiḿenez, Maria ; Dess, Robert T. ; Davis, John W. ; Den, Robert B. ; Dicker, Adam P. ; Kane, Christopher J. ; Pollack, Alan ; Stoyanova, Radka ; Abdollah, Firas ; Ross, Ashley E. ; Cole, Adam ; Uchio, Edward ; Randall, Josh M. ; Nguyen, Hao ; Zhao, Shuang G. ; Mehra, Rohit ; Glass, Andrew G. ; Lam, Lucia L.C. ; Chelliserry, Jijumon ; Du Plessis, Marguerite ; Choeurng, Voleak ; Aranes, Maria ; Kolisnik, Tyler ; Margrave, Jennifer ; Alter, Jason ; Jordan, Jennifer ; Buerki, Christine ; Yousefi, Kasra ; Haddad, Zaid ; Davicioni, Elai ; Trabulsi, Edouard J. ; Loeb, Stacy ; Tewari, Ashutosh ; Carroll, Peter R. ; Weinmann, Sheila ; Schaeffer, Edward M. ; Klein, Eric A. ; Karnes, R. Jeffrey ; Feng, Felix Y. ; Nguyen, Paul L. / Development and validation of a novel integrated clinical-genomic risk group classification for localized prostate cancer. In: Journal of Clinical Oncology. 2018 ; Vol. 36, No. 6. pp. 581-590.
@article{05847bbcdde04adc95041447dbaff0b2,
title = "Development and validation of a novel integrated clinical-genomic risk group classification for localized prostate cancer",
abstract = "Purpose It is clinically challenging to integrate genomic-classifier results that report a numeric risk of recurrence into treatment recommendations for localized prostate cancer, which are founded in the framework of risk groups. We aimed to develop a novel clinical-genomic risk grouping system that can readily be incorporated into treatment guidelines for localized prostate cancer. Materials and Methods Two multicenter cohorts (n = 991) were used for training and validation of the clinical-genomic risk groups, and two additional cohorts (n = 5,937) were used for reclassification analyses. Competing risks analysis was used to estimate the risk of distant metastasis. Time-dependent c-indices were constructed to compare clinicopathologic risk models with the clinical-genomic risk groups. Results With a median follow-up of 8 years for patients in the training cohort, 10-year distant metastasis rates for National Comprehensive Cancer Network (NCCN) low, favorable-intermediate, unfavorableintermediate, and high-risk were 7.3{\%}, 9.2{\%}, 38.0{\%}, and 39.5{\%}, respectively. In contrast, the threetier clinical-genomic risk groups had 10-year distant metastasis rates of 3.5{\%}, 29.4{\%}, and 54.6{\%}, for low-, intermediate-, and high-risk, respectively, which were consistent in the validation cohort (0{\%}, 25.9{\%}, and 55.2{\%}, respectively). C-indices for the clinical-genomic risk grouping system (0.84; 95{\%} CI, 0.61 to 0.93) were improved over NCCN (0.73; 95{\%} CI, 0.60 to 0.86) and Cancer of the Prostate Risk Assessment (0.74; 95{\%}CI, 0.65 to 0.84), and 30{\%}of patients using NCCN low/intermediate/high would be reclassified by the new three-tier system and 67{\%} of patients would be reclassified from NCCN six-tier (very-low- to very-high-risk) by the new six-tier system. Conclusion A commercially available genomic classifier in combination with standard clinicopathologic variables can generate a simple-to-use clinical-genomic risk grouping that more accurately identifies patients at low, intermediate, and high risk formetastasis and can be easily incorporated into current guidelines to better risk-stratify patients.",
author = "Spratt, {Daniel E.} and Jingbin Zhang and Maria Santiago-Jiḿenez and Dess, {Robert T.} and Davis, {John W.} and Den, {Robert B.} and Dicker, {Adam P.} and Kane, {Christopher J.} and Alan Pollack and Radka Stoyanova and Firas Abdollah and Ross, {Ashley E.} and Adam Cole and Edward Uchio and Randall, {Josh M.} and Hao Nguyen and Zhao, {Shuang G.} and Rohit Mehra and Glass, {Andrew G.} and Lam, {Lucia L.C.} and Jijumon Chelliserry and {Du Plessis}, Marguerite and Voleak Choeurng and Maria Aranes and Tyler Kolisnik and Jennifer Margrave and Jason Alter and Jennifer Jordan and Christine Buerki and Kasra Yousefi and Zaid Haddad and Elai Davicioni and Trabulsi, {Edouard J.} and Stacy Loeb and Ashutosh Tewari and Carroll, {Peter R.} and Sheila Weinmann and Schaeffer, {Edward M.} and Klein, {Eric A.} and Karnes, {R. Jeffrey} and Feng, {Felix Y.} and Nguyen, {Paul L.}",
year = "2018",
month = "2",
day = "20",
doi = "10.1200/JCO.2017.74.2940",
language = "English (US)",
volume = "36",
pages = "581--590",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "6",

}

TY - JOUR

T1 - Development and validation of a novel integrated clinical-genomic risk group classification for localized prostate cancer

AU - Spratt, Daniel E.

AU - Zhang, Jingbin

AU - Santiago-Jiḿenez, Maria

AU - Dess, Robert T.

AU - Davis, John W.

AU - Den, Robert B.

AU - Dicker, Adam P.

AU - Kane, Christopher J.

AU - Pollack, Alan

AU - Stoyanova, Radka

AU - Abdollah, Firas

AU - Ross, Ashley E.

AU - Cole, Adam

AU - Uchio, Edward

AU - Randall, Josh M.

AU - Nguyen, Hao

AU - Zhao, Shuang G.

AU - Mehra, Rohit

AU - Glass, Andrew G.

AU - Lam, Lucia L.C.

AU - Chelliserry, Jijumon

AU - Du Plessis, Marguerite

AU - Choeurng, Voleak

AU - Aranes, Maria

AU - Kolisnik, Tyler

AU - Margrave, Jennifer

AU - Alter, Jason

AU - Jordan, Jennifer

AU - Buerki, Christine

AU - Yousefi, Kasra

AU - Haddad, Zaid

AU - Davicioni, Elai

AU - Trabulsi, Edouard J.

AU - Loeb, Stacy

AU - Tewari, Ashutosh

AU - Carroll, Peter R.

AU - Weinmann, Sheila

AU - Schaeffer, Edward M.

AU - Klein, Eric A.

AU - Karnes, R. Jeffrey

AU - Feng, Felix Y.

AU - Nguyen, Paul L.

PY - 2018/2/20

Y1 - 2018/2/20

N2 - Purpose It is clinically challenging to integrate genomic-classifier results that report a numeric risk of recurrence into treatment recommendations for localized prostate cancer, which are founded in the framework of risk groups. We aimed to develop a novel clinical-genomic risk grouping system that can readily be incorporated into treatment guidelines for localized prostate cancer. Materials and Methods Two multicenter cohorts (n = 991) were used for training and validation of the clinical-genomic risk groups, and two additional cohorts (n = 5,937) were used for reclassification analyses. Competing risks analysis was used to estimate the risk of distant metastasis. Time-dependent c-indices were constructed to compare clinicopathologic risk models with the clinical-genomic risk groups. Results With a median follow-up of 8 years for patients in the training cohort, 10-year distant metastasis rates for National Comprehensive Cancer Network (NCCN) low, favorable-intermediate, unfavorableintermediate, and high-risk were 7.3%, 9.2%, 38.0%, and 39.5%, respectively. In contrast, the threetier clinical-genomic risk groups had 10-year distant metastasis rates of 3.5%, 29.4%, and 54.6%, for low-, intermediate-, and high-risk, respectively, which were consistent in the validation cohort (0%, 25.9%, and 55.2%, respectively). C-indices for the clinical-genomic risk grouping system (0.84; 95% CI, 0.61 to 0.93) were improved over NCCN (0.73; 95% CI, 0.60 to 0.86) and Cancer of the Prostate Risk Assessment (0.74; 95%CI, 0.65 to 0.84), and 30%of patients using NCCN low/intermediate/high would be reclassified by the new three-tier system and 67% of patients would be reclassified from NCCN six-tier (very-low- to very-high-risk) by the new six-tier system. Conclusion A commercially available genomic classifier in combination with standard clinicopathologic variables can generate a simple-to-use clinical-genomic risk grouping that more accurately identifies patients at low, intermediate, and high risk formetastasis and can be easily incorporated into current guidelines to better risk-stratify patients.

AB - Purpose It is clinically challenging to integrate genomic-classifier results that report a numeric risk of recurrence into treatment recommendations for localized prostate cancer, which are founded in the framework of risk groups. We aimed to develop a novel clinical-genomic risk grouping system that can readily be incorporated into treatment guidelines for localized prostate cancer. Materials and Methods Two multicenter cohorts (n = 991) were used for training and validation of the clinical-genomic risk groups, and two additional cohorts (n = 5,937) were used for reclassification analyses. Competing risks analysis was used to estimate the risk of distant metastasis. Time-dependent c-indices were constructed to compare clinicopathologic risk models with the clinical-genomic risk groups. Results With a median follow-up of 8 years for patients in the training cohort, 10-year distant metastasis rates for National Comprehensive Cancer Network (NCCN) low, favorable-intermediate, unfavorableintermediate, and high-risk were 7.3%, 9.2%, 38.0%, and 39.5%, respectively. In contrast, the threetier clinical-genomic risk groups had 10-year distant metastasis rates of 3.5%, 29.4%, and 54.6%, for low-, intermediate-, and high-risk, respectively, which were consistent in the validation cohort (0%, 25.9%, and 55.2%, respectively). C-indices for the clinical-genomic risk grouping system (0.84; 95% CI, 0.61 to 0.93) were improved over NCCN (0.73; 95% CI, 0.60 to 0.86) and Cancer of the Prostate Risk Assessment (0.74; 95%CI, 0.65 to 0.84), and 30%of patients using NCCN low/intermediate/high would be reclassified by the new three-tier system and 67% of patients would be reclassified from NCCN six-tier (very-low- to very-high-risk) by the new six-tier system. Conclusion A commercially available genomic classifier in combination with standard clinicopathologic variables can generate a simple-to-use clinical-genomic risk grouping that more accurately identifies patients at low, intermediate, and high risk formetastasis and can be easily incorporated into current guidelines to better risk-stratify patients.

UR - http://www.scopus.com/inward/record.url?scp=85040829382&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85040829382&partnerID=8YFLogxK

U2 - 10.1200/JCO.2017.74.2940

DO - 10.1200/JCO.2017.74.2940

M3 - Article

C2 - 29185869

AN - SCOPUS:85040829382

VL - 36

SP - 581

EP - 590

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 6

ER -